Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has shared an announcement.
Cinclus Pharma will publish its fourth-quarter 2025 report on 18 February 2026 at 08:00 CET and follow with a live presentation at 10:00 CET, led by CEO Christer Ahlberg, Interim CFO Patrik Norgren and R&D Director Margit Mahlapuu, including a Q&A session accessible via webcast and teleconference. The company will make the report, presentation materials and a recorded replay available on its website, underlining its effort to maintain active communication with investors and other stakeholders as it progresses its late-stage GERD drug candidate, linaprazan glurate, through Phase III development.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a Stockholm-based late-stage clinical pharmaceutical company focused on developing treatments for acid-related diseases and upper gastrointestinal disorders. Its lead drug candidate, linaprazan glurate, a prodrug of the P-CAB linaprazan originally developed by AstraZeneca, targets gastroesophageal reflux disease (GERD) and aims to offer more effective mucosal healing and symptom relief than current proton pump inhibitor therapies, addressing an unmet need among millions of severe GERD patients in the US and EU.
Average Trading Volume: 45,559
Technical Sentiment Signal: Sell
Current Market Cap: SEK804.2M
For a thorough assessment of CINPHA stock, go to TipRanks’ Stock Analysis page.